Website
News25/Ratings7
News · 26 weeks76-93%
2025-10-262026-04-19
Mix3590d
- Insider20(57%)
- SEC Filings11(31%)
- Earnings2(6%)
- Other1(3%)
- Offering1(3%)
Latest news
25 items- PRSERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF FIRST QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON MAY 6, 2026SALT LAKE CITY, April 22, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced it will report first quarter fiscal year 2026 financial results on Wednesday May 6, 2026, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m. Eastern Time. A press release outlining the financial results and highlights will be publicly distributed before the call.
- SECSEC Form 144 filed by Sera Prognostics Inc.144 - SERA PROGNOSTICS, INC. (0001534969) (Subject)
- SECSEC Form 144 filed by Sera Prognostics Inc.144 - SERA PROGNOSTICS, INC. (0001534969) (Subject)
- SECSEC Form 424B5 filed by Sera Prognostics Inc.424B5 - SERA PROGNOSTICS, INC. (0001534969) (Filer)
- SECSEC Form S-8 filed by Sera Prognostics Inc.S-8 - SERA PROGNOSTICS, INC. (0001534969) (Filer)
- SECSEC Form 10-K filed by Sera Prognostics Inc.10-K - SERA PROGNOSTICS, INC. (0001534969) (Filer)
- SECSera Prognostics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - SERA PROGNOSTICS, INC. (0001534969) (Filer)
- PRSERA PROGNOSTICS REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTSSALT LAKE CITY, March 18, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the fourth quarter and full year ended December 31, 2025. Key 2025 and Recent Highlights:Data Generation Published Landmark PRIME Study Demonstrating PreTRM® Blood Test Reduces Earliest Preterm Births and Newborn Complications: In January 2026, the PRIME Study, a randomized controlled trial of 5,018 women,
- INSIDERChief Executive Officer Lindgardt Zhenya was granted 154,440 shares, increasing direct ownership by 21% to 892,754 units (SEC Form 4)4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)
- INSIDERGeneral Counsel Jackson Benjamin was granted 44,215 shares, increasing direct ownership by 39% to 158,935 units (SEC Form 4)4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)
- INSIDERChief Medical Officer Inglis Tiffany Eul Davis was granted 17,437 shares, increasing direct ownership by 23% to 92,437 units (SEC Form 4)4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)
- INSIDERChief Commercial Officer Anderson Dyaarl Lee Jr. was granted 12,455 shares, increasing direct ownership by 19% to 79,569 units (SEC Form 4)4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)
- INSIDERChief Financial Officer Aerts Austin was granted 44,215 shares, increasing direct ownership by 17% to 308,667 units (SEC Form 4)4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)
- INSIDERChief Executive Officer Lindgardt Zhenya sold $49,079 worth of shares (25,612 units at $1.92), decreasing direct ownership by 3% to 738,314 units (SEC Form 4)4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)
- INSIDERChief Data Officer Kearney Paul sold $2,848 worth of shares (1,396 units at $2.04), decreasing direct ownership by 0.84% to 163,961 units (SEC Form 4)4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)
- INSIDERGeneral Counsel Jackson Benjamin sold $2,095 worth of shares (1,027 units at $2.04), decreasing direct ownership by 0.89% to 114,720 units (SEC Form 4)4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)
- INSIDERChief Information Officer Harrison Robert Gardner sold $1,461 worth of shares (716 units at $2.04), decreasing direct ownership by 0.92% to 76,712 units (SEC Form 4)4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)
- INSIDERChief Scientific Officer Boniface John J. sold $3,095 worth of shares (1,517 units at $2.04), decreasing direct ownership by 1% to 145,842 units (SEC Form 4)4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)
- INSIDERChief Financial Officer Aerts Austin sold $13,610 worth of shares (7,088 units at $1.92), decreasing direct ownership by 3% to 264,452 units (SEC Form 4)4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)
- SECSEC Form 144 filed by Sera Prognostics Inc.144 - SERA PROGNOSTICS, INC. (0001534969) (Subject)
- INSIDERSEC Form 4 filed by Sera Prognostics Inc.4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)
- INSIDERSEC Form 4 filed by Sera Prognostics Inc.4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)
- INSIDERSEC Form 4 filed by Sera Prognostics Inc.4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)
- INSIDERChief Scientific Officer Boniface John J. sold $5,954 worth of shares (3,038 units at $1.96), decreasing direct ownership by 2% to 147,359 units (SEC Form 4)4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)
- INSIDERChief Data Officer Kearney Paul sold $3,971 worth of shares (2,026 units at $1.96), decreasing direct ownership by 1% to 165,357 units (SEC Form 4)4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)